Charles River Laboratories International (NYSE:CRL) Trading 5.2% Higher – Here’s What Happened

Charles River Laboratories International, Inc. (NYSE:CRL) was up 5.2% during trading on Thursday . The stock traded as high as $294.24 and last traded at $291.7270. 81,426 shares were traded during mid-day trading, a decline of 91% from the average session volume of 923,697 shares. The stock had previously closed at $277.33.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Evercore reaffirmed an “outperform” rating and set a $320.00 price target on shares of Charles River Laboratories International in a research note on Friday, September 11th. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Piper Sandler set a $300.00 price objective on Charles River Laboratories International in a report on Monday, August 10th. BNP Paribas Exane set a $250.00 target price on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Finally, Barclays reaffirmed an “overweight” rating and issued a $300.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Eleven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $273.81.

Charles River Laboratories International Stock Performance

The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The company has a market cap of $13.95 billion, a price-to-earnings ratio of -60.26, a P/E/G ratio of 2.80 and a beta of 1.40. The stock has a 50 day moving average price of $267.76 and a two-hundred day moving average price of $211.63.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The firm’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Analysts predict that Charles River Laboratories International, Inc. will post 11.33 EPS for the current year.

Insider Activity at Charles River Laboratories International

In other news, EVP Shannon Parisotto sold 5,046 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total value of $1,327,098.00. Following the completion of the sale, the executive vice president directly owned 4,807 shares of the company’s stock, valued at $1,264,241. This represents a 51.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria L. Creamer sold 4,179 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the sale, the executive vice president owned 30,051 shares in the company, valued at $7,788,017.16. This represents a 12.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 165,990 shares of company stock worth $42,606,388. 1.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Several hedge funds have recently bought and sold shares of CRL. Continuum Advisory LLC bought a new position in shares of Charles River Laboratories International during the second quarter worth $30,000. Allworth Financial LP raised its stake in Charles River Laboratories International by 61.3% during the 4th quarter. Allworth Financial LP now owns 350 shares of the medical research company’s stock worth $70,000 after buying an additional 133 shares during the period. SHP Wealth Management acquired a new stake in Charles River Laboratories International during the 4th quarter worth $85,000. Eurizon Capital SGR S.p.A. bought a new position in Charles River Laboratories International during the fourth quarter worth about $104,000. Finally, Hilltop National Bank lifted its holdings in Charles River Laboratories International by 28.7% during the second quarter. Hilltop National Bank now owns 569 shares of the medical research company’s stock worth $129,000 after acquiring an additional 127 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.